AXSM (Axsome Corp) Market Value to Book Value Ratio
Axsome Therapeutics (AXSM) is expanding its influence in neuroscience by acquiring ready-made commercial systems, as clearly demonstrated by the price action on this chart. Business profitability relies on the sale of certified products and support from insurance companies, with the indicator standing at 91.04. Localizing all research in stable regions minimizes external risks, ensuring the seamless launch of new products into the global market.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_AXSM_-_Axsome-Therapeutics_-_Capitalization-to-Book-Value-Ratio "AXSM Axsome Therapeutics, Inc. Market Capitalization to Book Value Ratio (07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Axsome (AXSM)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Axsome Therapeutics - AXSM
As a biopharmaceutical developer in the field of neurology with strict adherence to ESG standards, Axsome Therapeutics (AXSM) is valued by the market through the prism of its intellectual and tangible assets. This market value-to-book value ratio measures the gap between the stock price and the actual value of capital, helping investors determine the extent to which the business is overvalued relative to its accounting base.
Main competitors
BIIB (Biogen Inc.) - Market Value to Book Value Ratio|NBIX (neurocrine.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio ACADIA Pharma|Xenon Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Viking Therapeutics Corp VKTX|Market Cap to Net Assets Ratio SUPN (Supernus Pharmaceuticals)|catalystpharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Denali Therapeutics Inc. (DNLI)|HRMY: Market Value to Book Value|Market Value to Book Value Ratio BHVN|Amylyx Corp (AMLX) - Market-to-Book Ratio|TRVI (Trevi Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio praxismedicines.com (PRAX)|Market Cap to Net Assets Ratio Anavex Life Sciences Corp. AVXL|Capitalization to Book Value Ratio CBLL (CeriBell Inc)|Market Value to Book Value Ratio PRTA|Alector Inc. - Market Capitalization to Book Value|ANNX (Annexon, Inc.) - Market Value to Book Value Ratio|OMER: Market-to-Book Ratio|NGNE (Neurogene) - Market Value to Book Value Ratio|AC Immune S.A. (ACIU) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VYGR (Voyager Pharma)|Market-to-Book Ratio Neumora Corp (NMRA)|Scilex Holding Company (SCLX) - Market Cap to Net Assets Ratio|Market Value to Book Value tevogen.com TVGN|Market Cap to Net Assets Ratio Alpha Cognition Inc. (ACOG)|Market Cap to Book Value Multiple cogrx.com CGTX|Market Capitalization to Book Value Ratio Inhibikase (IKT)|SAVA - Market Value to Book Value|Market Capitalization to Book Value Ratio ASRT|COYA (Coya Therapeutics) - Market-to-Book Ratio|VTGN - Market Value to Book Value Ratio|Market Value to Book Value Ovid Rx|Market Capitalization to Book Value Ratio ABOS|Market Capitalization to Book Value Ratio CRVO (CervoMed Corporation)|Alterity Therapeutics Limited (ATHE) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Clene Inc CLNN|PEPG (PepGen Corp) - Market Capitalization to Book Value Ratio|jupiterneurosciences.com (JUNS) - Market-to-Book Ratio|RLMD: Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Annovis Bio Corporation|Grace Therapeutics Inc (GRCE) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple fireflyneuro.com|KLTO (Klotho Neurosciences Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value neurosense-tx.com (NRSN)|Reviva Pharmaceuticals Holdings - Market Capitalization to Book Value Ratio|MetaVia Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio NRXS (NeurAxis, Inc.)|HSDT - Market Capitalization to Book Value|PASG: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Neuphoria Therapeutics|Market Cap to Net Assets Ratio Minerva Neurosciences Corp (NERV)|Capitalization to Book Value Ratio ATHA|ADXN (Addex Therapeutics) - Market Value to Book Value Ratio|Market Capitalization to Book Value ALZN (alzamend.com)|Cyclerion Therapeutics, Inc. - Market Value to Book Value Ratio|Protagenic Therapeutics Inc. - Market Cap to Net Assets Ratio|Pasithea (KTTA) - Market Value to Book Value Ratio|CRGT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ATXI|Market-to-Book Ratio brainstorm-cell.com|CARA (Cara Therapeutics) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio CHRO|Eliem Therapeutics (ELYM) - Market Value to Book Value Ratio|Market Value to Book Value ITCI (intracellulartherapies.com)|LBPH: Market Value to Book Value Ratio|Market-to-Book Ratio marinuspharma.com MRNS|NKGen Biotech - Market Capitalization to Book Value Ratio|NeuroBo Pharmaceuticals Inc (NRBO) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Sage Therapeutics, Inc|SNPX (Synaptogenix, Inc) - Capitalization to Book Value Ratio|TRVN: Market Value to Book Value Ratio|Market Capitalization to Book Value VIGL|Anew Medical, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio CERE (Cerevel Therapeutics Inc)